Is RNXT or SPRO more profitable?

SPRO runs the higher net margin — RNXT at -621.71% versus SPRO at 17.18%.

How have RNXT and SPRO total returns compared?

Over the past 5 years, RNXT delivered -23.80% and SPRO delivered -42.70% annualized total return. Past performance doesn't predict future results.

RenovoRx, Inc. (RNXT) vs Spero Therapeutics, Inc. (SPRO)

A side-by-side comparison of RenovoRx, Inc. and Spero Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

RNXT

RenovoRx, Inc.

$63M

$1.39HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

SPRO

Spero Therapeutics, Inc.

$69M

$1.19HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — RNXT vs SPRO

growth of $100 · dividends reinvested · last 5y

RNXT -79.8% (-27.3%/yr)SPRO -92.9% (-41.0%/yr)RNXT compounded faster over this window

RNXT SPRO

RNXT vs SPRO: by the numbers

•SPRO is the larger company ($69M vs $63M market cap).
•SPRO is profitable (17.18% net margin) while RNXT runs a net loss (-621.71%).

Metrics side by side

Valuation

Metric	RNXT	SPRO
P/E ratio	N/A	10.82
P/S ratio	31.69	1.60
P/B ratio	6.97	1.56
EV / EBITDA	N/A	3.35
FCF yield	N/A	28.42%

Profitability

Metric	RNXT	SPRO
Gross margin	70.88%	100.00%
Operating margin	-1113.98%	-0.04%
Net margin	-621.71%	17.18%
ROE	-136.82%	16.70%
ROIC	-139.74%	13.12%

Growth (annualized)

Metric	RNXT	SPRO
Revenue CAGR (5Y)	N/A	22.93%
Total return CAGR (5Y)	-23.80%	-42.70%

Frequently asked

Is RNXT or SPRO more profitable?: SPRO runs the higher net margin — RNXT at -621.71% versus SPRO at 17.18%.
How have RNXT and SPRO total returns compared?: Over the past 5 years, RNXT delivered -23.80% and SPRO delivered -42.70% annualized total return. Past performance doesn't predict future results.

Go deeper

Full RNXT analysis Full SPRO analysis Interactive comparison tool

Dig into the metrics

Spero Therapeutics P/E ratio RenovoRx ROE Spero Therapeutics ROE RenovoRx operating margin Spero Therapeutics operating margin RenovoRx revenue growth Spero Therapeutics revenue growth RenovoRx free cash flow Spero Therapeutics free cash flow

RenovoRx & Spero Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.